Stem Cell Therapy for Cerebral Palsy
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Advanced MSC treatments to improve motor function, reduce spasticity, and enhance cognitive and speech abilities in children with CP. 500+ pediatric patients treated.
Can stem cell therapy help cerebral palsy?
Mesenchymal stem cell therapy is not an approved treatment for cerebral palsy. Several small trials — mostly using umbilical-cord-derived cells in children — have reported acceptable safety and modest changes on motor scales such as GMFM, but effect sizes have been inconsistent and largely open-label. Established therapies — physiotherapy, occupational therapy, orthopaedic and spasticity management — remain the evidence-based care.
Key facts
- Approval status
- Not approved for cerebral palsy
- Trial findings
- Mostly open-label, GMFM changes inconsistent across studies
- Standard care
- PT, OT, spasticity management, orthopaedic care
What we know
- MSC and umbilical-cord cell trials in paediatric CP have reported short-term safety in monitored settings.
What remains uncertain
- Whether reported motor-scale changes exceed expectations from intensified rehabilitation alone.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Cerebral palsy
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — including controlled studies
- Randomised trials?
- Several randomised trials in children (mostly umbilical cord blood or MSC), with modest and inconsistent effects
- Main outcomes studied
- Gross Motor Function Measure
- Spasticity scales
- Developmental scales
- Safety
- Long-term evidence
- Limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Cerebral palsy — PubMed
- Randomised controlled trials — Cerebral palsy — PubMed
- Registered MSC trials — Cerebral palsy — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
What is Cerebral Palsy?
Cerebral palsy (CP) is a group of permanent movement disorders caused by abnormal brain development or damage to the developing brain, most often occurring before birth. It affects approximately 1 in 345 children worldwide, making it the most common motor disability in childhood.
While conventional therapies focus on managing symptoms through physical therapy and medication, stem cell therapy targets the underlying brain injury by promoting neural repair, reducing neuroinflammation, and supporting the formation of new neural connections that can improve motor function.
At StemCell Longevita, we have treated over 500 children with cerebral palsy using our specialized MSC protocols, with 75% of families reporting meaningful improvements in motor function, speech, and cognitive abilities.
How Stem Cell Therapy Helps Cerebral Palsy
Motor Function Improvement
MSCs promote neural repair and plasticity, helping children achieve new motor milestones including improved walking, fine motor skills, and coordination.
Spasticity Reduction
Stem cell therapy helps reduce muscle stiffness and spasticity, improving range of motion and making daily activities and physical therapy more effective.
Speech & Communication
Many children experience improvements in speech clarity, language comprehension, and communication abilities as neural pathways are repaired and strengthened.
Cognitive Enhancement
MSCs support cognitive development by promoting neurogenesis and synaptic connections, with many children showing improved attention, learning, and social interaction.
Treatment Process
Your step-by-step treatment journey at StemCell Longevita
Pediatric Assessment
Comprehensive neurological evaluation, GMFCS classification, MRI review, and developmental milestone assessment.
Family Consultation
Detailed discussion with parents about treatment expectations, personalized protocol design, and therapy goals.
MSC Preparation
Age-appropriate stem cell doses prepared from Wharton's jelly with 97% viability in our GMP-certified laboratory.
Gentle Administration
Child-friendly treatment environment with sedation options. Combined intrathecal and IV delivery for optimal results.
Rehabilitation Plan
Post-treatment rehabilitation guidance, progress tracking at 3, 6, and 12 months, and coordination with home therapists.
Patient Experiences
Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul
"After 8 years of decline, I finally feel like I'm moving forward again. The team in Istanbul gave me something my neurologist at home couldn't — hope backed by real results."
"Within three months of treatment, our daughter started calling us by name. Her teachers noticed the difference before we even told them about the therapy."
Understanding the regenerative approach for cerebral palsy
Cerebral palsy has different causes and functional presentations. A paediatric review considers developmental history, imaging, current therapies, and family goals before any regenerative approach is discussed.
This page is for information and does not replace advice from your usual specialist. Eligibility, delivery route, and follow-up are determined only after an individual medical review.
Who may be considered?
Candidacy is assessed individually from the child's diagnosis, functional presentation, medical history, imaging, and current rehabilitation plan:
- Children with a confirmed cerebral palsy diagnosis and current paediatric records
- Families able to share relevant imaging, therapy reports, and medication history
- Children whose travel and procedure risks can be assessed safely
- Families seeking an additional discussion alongside established rehabilitation and paediatric care
How the clinical pathway is planned
The recommended plan is individualised after records are reviewed; it is not a fixed, one-size-fits-all treatment package.
- 1
Remote medical-record review
The team reviews diagnosis, history, imaging or test results, current medication, and the goals you want to discuss.
- 2
Clinical suitability assessment
A clinician considers whether a regenerative approach can be discussed safely, including the delivery route and the need for any further testing.
- 3
Written plan before travel
If appropriate, you receive a written outline of the proposed approach, expected visit schedule, exclusions, and coordination arrangements.
- 4
In-person confirmation and follow-up
The plan is reconfirmed after an in-person assessment in Istanbul, with remote follow-up arranged after the visit.
What the approach is intended to address
Regenerative approaches for cerebral palsy are an area of continuing research. They should be assessed in the context of established rehabilitation, paediatric neurology, and realistic functional goals.
Evidence and outcomes vary by diagnosis, disease stage, delivery approach, and the individual. The consultation is the place to discuss what is known, what remains uncertain, and whether an approach is appropriate for you.
Expected timeline and follow-up
Following treatment, improvements emerge progressively as neural connections strengthen, continuing for 6-12 months:
- 1
Early improvements (1-3 months)
Parents commonly report improved muscle tone and reduced spasticity, better motor control and coordination, and early gains in feeding and swallowing.
- 2
Speech & cognition
Enhanced speech and communication and improved cognitive function and learning develop as neural pathways are repaired and strengthened.
- 3
Continued development (6-12 months)
Results continue to develop for 6-12 months, with improved overall independence. Follow-up treatments are recommended every 6-12 months.
When treatment may not be appropriate
While MSC therapy is safe for most patients, certain conditions may be contraindications. Treatment is not suitable in the following situations:
- Active cancer or ongoing chemotherapy/radiation treatment
- Active systemic infections requiring IV antibiotics
- Severe organ failure (end-stage kidney, liver, or heart failure)
- Pregnancy or planned pregnancy within 3 months
- Known allergy to any component used in cell processing
- Uncontrolled seizures
Our medical team conducts a thorough screening process to identify any contraindications before treatment. If stem cell therapy is not appropriate for your situation, we will advise you honestly.
Questions to discuss before deciding
Travel and care-coordination path
Treatment at StemCell Longevita is an all-inclusive medical-travel program from your first consultation to your 12-month follow-up:
- 1
Free online consultation & medical record review
Your journey begins with a free remote consultation. Our medical team reviews your medical records, imaging, and history to assess suitability — no travel required at this stage.
- 2
Written personalized protocol & treatment plan
You receive a written, personalized treatment protocol and plan detailing the recommended cell dosing, delivery route, and expected schedule for your condition.
- 3
Travel booking with clinic assistance
Our team assists with your travel arrangements. Every package includes VIP airport transfer and a 5-star hotel stay with breakfast included for you and an accompanying family member.
- 4
On-arrival medical evaluation in Istanbul
On arrival you undergo an in-person medical evaluation at the JCI-accredited Liv Hospital Ulus in Istanbul before treatment begins.
- 5
Treatment days
Treatment is administered over your stay, with a typical total stay of 3-5 days including evaluation, treatment, and monitoring.
- 6
Return home & 12-month telemedicine follow-up
After returning home you receive a 12-month telemedicine follow-up program with regular remote check-ins to track your progress.
All Regenerative Medicine Applications
Explore our comprehensive range of regenerative medicine applications for various conditions. Click any option to learn more.
Related Articles
Explore our in-depth research articles and guides on related treatments and therapies.
Cerebral Palsy & Regenerative Medicine: New Hope for Children
Discover how mesenchymal stem cell approaches are supporting the care landscape for cerebral palsy, offering potential motor function improvement and quality of life for children and families worldwide.
Read ArticleRegenerative Medicine Application for Autism Spectrum Disorder
Explore the promising potential of regenerative medicine in addressing autism spectrum disorder symptoms, including potential improvements in communication, social interaction, and behavioral patterns.
Read ArticleStroke Progress: How Stem Cells Support Neurological Wellness
Exploring the potential of regenerative medicine in stroke rehabilitation, including mechanisms of action and reported improvements in motor and cognitive function.
Read ArticleRelated clinical questions
Where this page sits in the wider picture.